Epitinib Succinate

琥珀酸依吡替尼

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameEpitinib Succinate
Drug Alias NameHuposuan yipitini琥珀酸易吡替尼Epitinib依吡替尼HMPL-813
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesHutchison Medipharma Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungGlioblastoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A